Overview

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer

Status:
Recruiting

Trial end date:
2032-01-01

Target enrollment:

Participant gender:

Summary

This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Cambridge University Hospitals NHS Foundation Trust

Collaborators:

AstraZeneca
Cancer Research UK

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Olaparib
Paclitaxel